From: Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways
Characteristics | CD8 Positive | Granzyme B Positive | Foxp3 Positive | IL17 Positive | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
 | ≤52.50 (n = 53) | > 52.50 (n = 53) | P | ≤32.45 (n = 53) | > 32.45 (n = 53) | P | ≤74.00 (n = 53) | >74.00 (n = 53) | P | ≤5.60 (n = 54) | >5.60 (n = 52) | P |
Age, years | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
≤49 | 27 | 27 |  | 21 | 34 |  | 24 | 31 |  | 27 | 28 |  |
>49 | 26 | 25 | 0.846 | 32 | 19 | 0.011* | 29 | 22 | 0.174 | 27 | 24 | 0.692 |
Gender | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Male | 41 | 43 | Â | 41 | 43 | Â | 39 | 44 | Â | 42 | 42 | Â |
Female | 12 | 10 | 0.632 | 12 | 10 | 0.632 | 14 | 8 | 0.359 | 12 | 10 | 0.704 |
Tumor (T) stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
T1+T2 | 28 | 29 | Â | 22 | 35 | Â | 21 | 36 | Â | 26 | 31 | Â |
T3+T4 | 25 | 24 | 0.846 | 31 | 18 | 0.011* | 32 | 17 | 0.003* | 28 | 21 | 0.236 |
Lymphoid Nodal (N) status | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
N0 | 13 | 5 | Â | 9 | 9 | Â | 10 | 8 | Â | 9 | 9 | Â |
N1-3 | 40 | 48 | 0.038* | 44 | 44 | 1.000 | 43 | 45 | 0.605 | 45 | 43 | 0.930 |
TNM Clinical stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
I+II | 21 | 17 | Â | 16 | 22 | Â | 14 | 24 | Â | 15 | 23 | Â |
III+IVa+IVb | 32 | 36 | 0.418 | 37 | 31 | 0.224 | 38 | 29 | 0.043* | 39 | 29 | 0.077 |
LMP1 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
- | 25 | 31 | Â | 30 | 26 | Â | 28 | 28 | Â | 31 | 25 | Â |
+ | 27 | 20 | 0.195 | 22 | 25 | 0.494 | 23 | 24 | 0.914 | 21 | 26 | 0.280 |